Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other non-.GEP-NET.

The treatment regimen will consist of 4 doses of 200 (±10%) mCi 177Lu-DOTATOC administered at 8+/- 1-week intervals.
Pulmonary Neuroendocrine Neoplasm|Pheochromocytoma|Paraganglioma|Thymus Carcinoid|Unknown Primary Tumors|Neuroendocrine Tumors|Neuroendocrine Skin Carcinoma|Neuroendocrine Breast Tumor|Neuroendocrine Carcinoma Metastatic|Neuroendocrine Neoplasm of Ovary
DRUG: 177Lu-DOTATOC
Assessment of the overall response rate, determined using standard of care scans NETSPOT PET/CT, Octreoscan SPECT/CT, MRI, 12 monts
Progression Free Survival (rPFS) in subjects receiving 4 cycles of therapy Monitoring of the changes in quality of life (QOL) through assessment of ECOG performance status and a QOL subject questionnaire., determined using standard of care scans NETSPOT PET/CT, Octreoscan SPECT/CT, MRI, 12 months
Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other non-.GEP-NET.

The treatment regimen will consist of 4 doses of 200 (±10%) mCi 177Lu-DOTATOC administered at 8+/- 1-week intervals.